<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30043916</article-id><article-id pub-id-type="pmc">6089136</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0081</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Rational Use of Mechanical Circulatory Support as a Bridge to
Pediatric and Congenital Heart Transplantation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miana</surname><given-names>Leonardo A.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>Guilherme Viotto Rodrigues</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Caneo</surname><given-names>Luiz Fernando</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Turquetto</surname><given-names>Aida Luisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>RRT, PhD</role></contrib><contrib contrib-type="author"><name><surname>Tanamati</surname><given-names>Carla</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Foronda</surname><given-names>Gustavo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Massoti</surname><given-names>Maria Raquel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Penha</surname><given-names>Juliano G.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Azeka</surname><given-names>Estela</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Galas</surname><given-names>Filomena R. B. G.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Jatene</surname><given-names>Fabio B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Jatene</surname><given-names>Marcelo B.</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD, PhD</role></contrib><aff id="aff1">
<label>1</label>Cardiovascular Surgery Division, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP), S&#x000e3;o Paulo, SP,
Brazil.</aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Leonardo A Miana, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP) - Pediatric Cardiac Surgery
Unit, Av. Dr. Eneas de Carvalho Aguiar, 44 - Bloco II, 2&#x000b0; andar - S&#x000e3;o
Paulo, SP, Brazil, Zip code: 05403-900. E-mail:
<email>leonardomiana@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>May-Jun</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>May-Jun</season><year>2018</year></pub-date><volume>33</volume><issue>3</issue><fpage>242</fpage><lpage>249</lpage><history><date date-type="received"><day>15</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>15</day><month>3</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Donor shortage and organ allocation is the main problem in pediatric heart
transplant. Mechanical circulatory support is known to increase waiting list
survival, but it is not routinely used in pediatric programs in Latin
America.</p></sec><sec><title>Methods</title><p>All patients listed for heart transplant and supported by a mechanical
circulatory support between January 2012 and March 2016 were included in
this retrospective single-center study. The endpoints were mechanical
circulatory support time, complications, heart transplant survival and
discharge from the hospital.</p></sec><sec><title>Results</title><p>Twenty-nine patients from our waiting list were assessed. Twelve (45%)
patients were initially supported by extracorporeal membrane oxygenation
(ECMO) and a centrifugal pump was implanted in 17 (55%) patients. Five
patients initially supported by ECMO were bridged to another device. One was
bridged to a centrifugal pump and four were bridged to Berlin Heart
Excor&#x000ae;. Among the 29 supported patients, 18 (62%) managed to have a
heart transplant. Thirty-day survival period after heart transplant was 56%
(10 patients). Median support duration was 12 days (interquartile range
[IQR] 4 - 26 days) per run and the waiting time for heart transplant was 9.5
days (IQR 2.5-25 days). Acute kidney injury was identified as a mortality
predictor (OR=22.6 [CI=1.04-494.6]; <italic>P</italic>=0.04).</p></sec><sec><title>Conclusion</title><p>Mechanical circulatory support was able to bridge most INTERMACS 1 and 2
pediatric patients to transplant with an acceptable complication rate. Acute
renal failure increased mortality after mechanical circulatory support in
our experience.</p></sec></abstract><kwd-group><kwd>Heart Transplantation</kwd><kwd>Heart Defects, Congenital</kwd><kwd>Heart-Assist Devices</kwd><kwd>Heart Failure/Therapy</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="float"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AKI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute kidney injury</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Mechanical circulatory
support</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BNP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Brain natriuretic
peptide</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MODs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Multiple organs
dysfunction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CHD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Congenital heart
disease</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">pRIFLE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Pediatric risk, injury,
failure, loss, end stage renal disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Right ventricle; right
ventricular</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Computed tomography</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SIRS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Systemic inflammatory
response syndrome</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ECMO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Extracorporeal membrane
oxygenation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TEE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transesophageal
echocardiography</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HTx</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heart
transplantation</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">UFH</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Unfractionated
heparin</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IQR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interquartile range</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">USA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= United States of
America</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricle</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ventricular assist
device</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MCD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Massive cerebral
damages</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Heart failure is a complex pathophysiological syndrome that can occur in children due
to a variety of diseases, including cardiomyopathies, myocarditis, and congenital
heart disease (CHD)<sup>[</sup><sup><xref rid="r1" ref-type="bibr">1</xref></sup><sup>]</sup>. The incidence of dilated cardiomyopathy from large
population-based studies in the United States and Australia range from 0.57 to 0.73
per 100000 children per year<sup>[</sup><sup><xref rid="r2" ref-type="bibr">2</xref></sup><sup>,</sup><sup><xref rid="r3" ref-type="bibr">3</xref></sup><sup>]</sup>. Among these patients, only 66% were alive without
heart transplant one year after diagnosis<sup>[</sup><sup><xref rid="r4" ref-type="bibr">4</xref></sup><sup>]</sup>.</p><p>Heart transplantation (HTx) is increasingly accepted as the gold-standard treatment
for end stage heart disease (either functional, anatomic or both) in the pediatric
and adult congenital population<sup>[</sup><sup><xref rid="r5" ref-type="bibr">5</xref></sup><sup>,</sup><sup><xref rid="r6" ref-type="bibr">6</xref></sup><sup>]</sup>. Donor shortage and difficulties in allocation
increase mortality during the waiting list for transplantation, specifically in
low-weight receptors, and high-risk congenital heart and cardiomyopathy patients
that develop cardiogenic shock<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>]</sup>.</p><p>The use of mechanical circulatory support (MCS) systems as a bridge to
transplantation or bridge to recovery are the main indications in infants and
children<sup>[</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>-</sup><sup><xref rid="r11" ref-type="bibr">11</xref></sup><sup>]</sup>. Recently published data from the International
Society for Heart and Lung Transplantation reported that approximately 25% of
pediatric patients receive some kind of MCS before HTx<sup>[</sup><sup><xref rid="r12" ref-type="bibr">12</xref></sup><sup>]</sup>. Long and short-term
MCS is associated with higher survival to HTx in these
patients<sup>[</sup><sup><xref rid="r13" ref-type="bibr">13</xref></sup><sup>]</sup>.</p><p>Although the majority of Latin America countries faces serious economic issues, in
order to increase survival in advanced heart failure, the implementation of MCS
programs is welcome in these locations.</p><p>The waiting list time in Latin America is three times higher than in United States of
America (USA) and two times higher than in Europe<sup>[</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>]</sup>. Mean waiting list time
for transplantation in Brazil is 6 months, but in patients less than 5 kg this
period is greater than 10 months<sup>[</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>]</sup>.</p><p>HTx program in Brazil is financed by the government and until now, there is no
financial support for any kind of MCS. Nevertheless, a small percentage of patients
are insurance covered that may have access to MCS technology and few Brazilian
institutions support an MCS program financed by research grants.</p><p>Our institution represents the largest Pediatric HTx Program in Latin America. We
have performed an average of 17 pediatric and congenital HTx annually in the last
five years, and our waiting list mortality, especially for the patients classified
as INTERMACS 1 and 2, is higher than 80%<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>,</sup><sup><xref rid="r13" ref-type="bibr">13</xref></sup><sup>]</sup>. Our MCS program is supported by our
institutional fund and restricted to extracorporeal membrane oxygenation (ECMO) and
centrifugal pumps (Rotaflow&#x000ae; - Maquet Getting Group, Rasttat, Germany).</p><p>The present study aims to evaluate initial results, risk factors, lessons learned and
future directions after this experience.</p><p>These are the first series of a mechanically supported bridge to transplant pediatric
and congenital heart patients including short and long-term support devices
published in Latin America.</p></sec><sec sec-type="methods"><title>METHODS</title><p>A retrospective study using electronic medical record of 29 consecutive patients
listed to HTx who required MCS between January 2012 and March 2016 at our
institution.</p><p>The institutional ethics committee on human research under the number CAAE
60236316.5.0000.0068 approved this study and due to the retrospective nature of the
study, the need for individual patient consent was waived.</p><sec><title>Timing and Indications</title><p>ECMO indications as a bridge to HTx or bridge to bridge was mainly in cardiogenic
shock or post-cardiotomy cardiac failure (INTERMACS level 1). Neck vessels
assessment was the elected cannulation site, but central cannulation was
approached when there was a recent previous sternotomy or in post-cardiotomy
patients.</p><p>Centrifugal pumps (Rotaflow&#x000ae; - Maquet Getting Group, Rasttat, Germany, and
PediVas&#x000ae; or Centrimag&#x000ae; - Thoratec Corporation, USA) were implanted
mainly in waiting list patients with rapid clinical deterioration despite
inotropic support (INTERMACS 2 level) or in two INTERMACS level 1 cases where an
ECMO circuit was not available at the time. Patients were cannulated using
bypass cannulas or Berlin Heart EXCOR&#x000ae; cannulas. The preferred
cannulation sites were left ventricle (LV) apex and aorta, but in the beginning
of the cohort and in restrictive cardiomyopathy cases, left atrium cannulation
was preferred. When LV cannulation was used, the procedure was performed under
cardiopulmonary bypass (CPB) and beating heart. When biventricular support was
indicated, right atrium and pulmonary artery were cannulated.</p><p>Right ventricular (RV) support was considered in the presence of severe RV
dysfunction or in case of moderate RV dysfunction with a central venous pressure
above 15 mmHg and persistently depressed RV function after LV decompression
guided by transesophageal echocardiography (TEE) at the operating room.</p><p>Berlin Heart Excor&#x000ae; was implanted in four cases, always after an ECMO run
for circulatory resuscitation. The implant was performed under CPB and beating
heart with LV apical and aortic cannulae.</p></sec><sec><title>Management</title><p>Device selection was performed based on the initial clinical status, where
INTERMACS level 1 was a primary indication for ECMO and INTERMACS level 2 was an
indication for a centrifugal pump. Due to our financial restriction, INTERMACS
level 3 was not an indication for MCS in our institution. In cases where ECMO
was the first-line therapy, conversion to centrifugal pump or Berlin Heart
Excor&#x000ae; was attempted after 5 to 10 days of ECMO initiation and clinical
stabilization. In two cases where an ECMO circuit was not available, MCS was
achieved using a centrifugal pump.</p><p>Conversion to a centrifugal pump was considered in one case in the context of the
potential for recovery (post-cardiotomy ECMO in a single ventricle physiology)
to minimize complications while performing a thorough transplant assessment
(<italic>e.g</italic>., neurologic assessment) and because renal replacement
therapy or respiratory support was not necessary at the time.</p><p>Conversion from a centrifugal pump to an ECMO circuit occurred in one patient who
developed multi-organ failure during centrifugal pump run and needed renal
replacement therapy and prolonged respiratory support.</p><p>Anti-coagulation was based on the Edmonton protocol<sup>[</sup><sup><xref rid="r14" ref-type="bibr">14</xref></sup><sup>]</sup> where
unfractionated heparin (UFH) was started within 12 to 24 hours of device
implantation, depending on the degree of postoperative bleeding based on chest
tube output. An acceptable chest tube output as a trigger for starting UFH was
considered if less than 2 ml/kg/h. UFH was titrated to a target anti-Xa level of
0.35 to 0.6 U/ml, with a goal activated clotting time range that correlated with
the anti-Xa target. Anti-coagulation goals and agents were adjusted individually
depending on the circuit condition as well as on the patient's bleeding and
thrombotic profile.</p></sec><sec><title>Outcomes</title><p>The primary outcome of this study was decannulation from any type of MCS due to
transplantation, recovery or death. Complete follow-up data were available for
all patients.</p><p>Five types of MCS-related complications were accessed in this cohort and included
bleeding, neurologic events, infection, ischemic organ damage, and mechanical
device failure.</p><p>Bleeding as the requirement for re-exploration for bleeding or hematoma were
considered significant.</p><p>Neurologic events included intracranial bleeding or ischemic stroke diagnosed by
computed tomography (CT) scan.</p><p>Infections were defined as the presence of positive culture from blood, urine,
intravenous catheter, or sputum with associated clinical symptoms. In the
absence of a defined positive culture, antibiotic use alone was not considered
as an evidence of infection, but clinical symptoms with suggestive laboratory
findings.</p><p>Acute kidney injury (AKI) in any time of treatment was defined according to
pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease (pRIFLE)
score<sup>[</sup><sup><xref rid="r15" ref-type="bibr">15</xref></sup><sup>]</sup>.</p><p>Finally, mechanical device failure was defined as a malfunction of one or more
components rendering the system incapable of functioning and requiring a device
exchange. This did not include exchanges for pump thrombosis or clots in the
circuit, considered as thrombotic events.</p><p>Circuit thrombosis included any identified cloth in the circuit with or without a
need for pump, membrane or complete circuit exchange.</p><p>All data were analyzed to identify risk factor for survival to transplantation,
survival to hospital discharge and stroke.</p><p>Studied risk factors included age, weight, gender, primary diagnosis
(cardiomyopathies x CHD), univentricular heart physiology, type of primary MCS
(ECMO x centrifugal pump), number of MCS implants, preoperative cardiac arrest,
preoperative AKI, AKI during hospitalization, stroke, preoperative mechanical
ventilation, systemic inflammatory response syndrome (SIRS), preoperative serum
creatinine value, preoperative serum total bilirubin value, preoperative serum
lactate value, preoperative serum brain natriuretic peptide (BNP) value,
infection, major bleeding and circuit thrombosis.</p><p>The time of support was considered as the time between the implantation and any
outcome (transplantation, explant or death).</p></sec><sec><title>Statistical Analysis</title><p>Descriptive statistics were presented in the median with interquartile range
(IQR) for continuous variables and number and percentile for the other
variables. Normality test used was Shapiro-Wilk. Chi square, Mann-Whitney, and
Exact Fisher test were used to compare groups. Binary logistic regression with
multivariable analysis and Hosmer-Lemeshow goodness of fit test was used to
identify risk factors for mortality and stroke. A <italic>P</italic> value &#x0003c;
0.05 was considered significant. The software SPSS 21.0 (SPSS, Chigago, IL, USA)
was used for statistical analysis.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Twenty-nine patients listed for HTx had at least one MCS implanted. Twelve patients
in refractory cardiogenic shock or postcardiotomy cardiac failure (INTERMACS level
1) were supported initially by an ECMO circuit. The other 17 patients, mostly
classified as INTERMACS level 2 underwent centrifugal pump implantation.</p><p>Demographic and preoperative variables are listed in <xref rid="t1" ref-type="table">Table 1</xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Pediatric and congenital heart transplant patients receiving mechanical
circulatory support demographics comparing centrifugal pump and ECMO
patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">All patients <break/>(n=29)</th><th align="center" rowspan="1" colspan="1">Centrifugal Pump<break/>(n=17)</th><th align="center" rowspan="1" colspan="1">ECMO<break/>(n=12)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age at implant (years), mean (IQR)</td><td align="center" rowspan="1" colspan="1">5.6 (1.8-12)</td><td align="center" rowspan="1" colspan="1">5.2 (1.8-9.5)</td><td align="center" rowspan="1" colspan="1">8.8 (1.5-19.4)</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight at implant (kg), mean (IQR)</td><td align="center" rowspan="1" colspan="1">16.7 (8.9-35)</td><td align="center" rowspan="1" colspan="1">16 (10.5-29)</td><td align="center" rowspan="1" colspan="1">24.5 (7.1-52.5)</td><td align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Male sex, N (%)</td><td align="center" rowspan="1" colspan="1">15 (51.7%)</td><td align="center" rowspan="1" colspan="1">8 (47%)</td><td align="center" rowspan="1" colspan="1">7 (58%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of MCS implant</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="2" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnosis at implant</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cardiomyopathy/myocarditis</td><td align="center" rowspan="1" colspan="1">21 (72.4%)</td><td align="center" rowspan="1" colspan="1">15 (88.2%)</td><td align="center" rowspan="1" colspan="1">6 (50%)</td><td align="center" rowspan="2" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Congenital heart disease</td><td align="center" rowspan="1" colspan="1">8 (27.6%)</td><td align="center" rowspan="1" colspan="1">2 (11.8%)</td><td align="center" rowspan="1" colspan="1">6 (50%)</td></tr><tr><td align="left" rowspan="1" colspan="1">MCS in postoperative cardiac surgery </td><td align="center" rowspan="1" colspan="1">6 (20.7%)</td><td align="center" rowspan="1" colspan="1">1 (5.9%)</td><td align="center" rowspan="1" colspan="1">5 (41.7%)</td><td align="center" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-MCS mechanical ventilation</td><td align="center" rowspan="1" colspan="1">20 (69%)</td><td align="center" rowspan="1" colspan="1">12 (70.6%)</td><td align="center" rowspan="1" colspan="1">8 (66.7%)</td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-MCS cardiac arrest, N (%)</td><td align="center" rowspan="1" colspan="1">16 (55.2%)</td><td align="center" rowspan="1" colspan="1">11 (64.7%)</td><td align="center" rowspan="1" colspan="1">5 (41.7%)</td><td align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-MCS AKI, N (%)</td><td align="center" rowspan="1" colspan="1">12 (41.4%)</td><td align="center" rowspan="1" colspan="1">6 (35.3%)</td><td align="center" rowspan="1" colspan="1">6 (50%)</td><td align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-MCS creatinine plasma levels, average (STD)</td><td align="center" rowspan="1" colspan="1">0.7 (0.4-1.06)</td><td align="center" rowspan="1" colspan="1">0.6 (0.4-0.8)</td><td align="center" rowspan="1" colspan="1">1 (0.4-1.4)</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-MCS total bilirubin plasma levels, average
(STD)</td><td align="center" rowspan="1" colspan="1">1 (1-1.5)</td><td align="center" rowspan="1" colspan="1">1 (1-2)</td><td align="center" rowspan="1" colspan="1">1 (0.7-1.3)</td><td align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-MCS arterial lactate plasma levels, average
(STD)</td><td align="center" rowspan="1" colspan="1">16 (13-26.5)</td><td align="center" rowspan="1" colspan="1">17 (13.5-25)</td><td align="center" rowspan="1" colspan="1">13.5 (13-26.7)</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Pre-MCS BNP plasma levels, average (STD)</td><td align="center" rowspan="1" colspan="1">2782 (1170-4466)</td><td align="center" rowspan="1" colspan="1">3207 (1560-4475)</td><td align="center" rowspan="1" colspan="1">1170 (454-4292)</td><td align="center" rowspan="1" colspan="1">0.2</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AKI=acute kidney injury; BNP=brain natriuretic peptide,
ECMO=extracorporeal membrane oxygenation; HTx=heart transplantation;
IQR=interquartile range; MCS=mechanical circulatory support;
STD=standard deviation</p></fn></table-wrap-foot></table-wrap><p>Five (41.7%) ECMO patients were bridged to another device before the HTx. One of them
received a centrifugal pump and the other four were connected to a paracorporeal
ventricular assist device (VAD; Berlin Heart Excor&#x000ae;). Two (16.7%) ECMO
patients died during MCS run. One patient died due to multiple organ failure and a
massive circuit thrombosis was found in the other patient leading to death. Six
(50%) patients received an HTx during ECMO run (<xref ref-type="fig" rid="f1">Figure
1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Outcomes in INTERMACS level 1 and 2 Pediatric and Congenital Heart
Transplant waiting list patients connected to MCS.</p></caption><graphic xlink:href="rbccv-33-03-0242-g01"/></fig>
</p><p>Among the four Berlin Heart patients, two (50%) were transplanted and two died during
MCS, one due to sepsis and one due to multiple organs dysfunction (MODs).</p><p>Seven (41.2%) centrifugal pump patients died during MCS run, five of them due to MODs
and two due to massive cerebral damages (MCD). While 58.8% (10 patients) managed to
have a HTx (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>Median time in MCS was 12.4 days (IQR= 4.3-26.3 days) and there was no correlation
between time on support and survival. There was no difference in time of support or
any other result variable between initial types of support (<xref rid="t2" ref-type="table">Table 2</xref>). HTx was achieved in 18 (62%) patients with 55.5% (10
patients) 30-day survival, while eight (44.5%) patients survived to discharge.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Pediatric and congenital heart transplant patients receiving mechanical
circulatory support results comparing centrifugal pump and ECMO
patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">All patients <break/>(n=29)</th><th align="center" rowspan="1" colspan="1">Centrifugal Pump<break/>(n=17)</th><th align="center" rowspan="1" colspan="1">ECMO<break/>(n=12)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Duration of support (days), mean (IQR)</td><td align="center" rowspan="1" colspan="1">12.4 (4.3-26.3)</td><td align="center" rowspan="1" colspan="1">12.4 (3-25)</td><td align="center" rowspan="1" colspan="1">13.3 (6-45)</td><td align="center" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Infective complication, n (%)</td><td align="center" rowspan="1" colspan="1">13 (44.8%)</td><td align="center" rowspan="1" colspan="1">6 (35.3%)</td><td align="center" rowspan="1" colspan="1">7 (58.3%)</td><td align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Circuit thrombus formation, n (%)</td><td align="center" rowspan="1" colspan="1">7 (24.1%)</td><td align="center" rowspan="1" colspan="1">3 (17.6%)</td><td align="center" rowspan="1" colspan="1">4 (33.3%)</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Chest reexploration, n (%)</td><td align="center" rowspan="1" colspan="1">7 (24.1%)</td><td align="center" rowspan="1" colspan="1">3 (17.6%)</td><td align="center" rowspan="1" colspan="1">4 (33.3%)</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">AKI during hospitalization, n (%)</td><td align="center" rowspan="1" colspan="1">15 (51.7%)</td><td align="center" rowspan="1" colspan="1">8 (47%)</td><td align="center" rowspan="1" colspan="1">7 (58.3%)</td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Cerebral injury - n (%)</td><td align="center" rowspan="1" colspan="1">17 (58.6%)</td><td align="center" rowspan="1" colspan="1">11 (64.7%)</td><td align="center" rowspan="1" colspan="1">6 (50%)</td><td align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Survival to Htx - n (%)</td><td align="center" rowspan="1" colspan="1">16 (55.2%)</td><td align="center" rowspan="1" colspan="1">10 (58.8%)</td><td align="center" rowspan="1" colspan="1">6 (50%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">30-day Survival - n (%)</td><td align="center" rowspan="1" colspan="1">10 (62.5%)</td><td align="center" rowspan="1" colspan="1">6 (60%)</td><td align="center" rowspan="1" colspan="1">4 (66.7%)</td><td align="center" rowspan="1" colspan="1">0.7</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AKI=acute kidney injury; BNP=brain natriuretic peptide;
ECMO=extracorporeal membrane oxygenation; HTx=heart transplantation;
IQR=Interquartile range; MCS=mechanical circulatory support;
STD=standard deviation</p></fn></table-wrap-foot></table-wrap><sec><title>Comparisons</title><p>All causes of post HTx death and patients characteristics are listed in <xref rid="t3" ref-type="table">Table 3</xref>.</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Causes of death after heart transplant.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Patient</th><th align="center" rowspan="1" colspan="1">Diagnosis</th><th align="center" rowspan="1" colspan="1">MCS</th><th align="center" rowspan="1" colspan="1">Duration of MCS (hours)</th><th align="center" rowspan="1" colspan="1">Cause of Death</th><th align="center" rowspan="1" colspan="1">Comments</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">MCP</td><td align="center" rowspan="1" colspan="1">CP</td><td align="center" rowspan="1" colspan="1">654</td><td align="center" rowspan="1" colspan="1">MCD</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">CHD (TOF)</td><td align="center" rowspan="1" colspan="1">CP</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">MCD</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">MCP</td><td align="center" rowspan="1" colspan="1">CP</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">CHD (SV)</td><td align="center" rowspan="1" colspan="1">CP</td><td align="center" rowspan="1" colspan="1">297</td><td align="center" rowspan="1" colspan="1">MOD</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">MCP</td><td align="center" rowspan="1" colspan="1">CP</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">Biventricular CP; ECPR 21 days post-HTx</td></tr><tr><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">MCP</td><td align="center" rowspan="1" colspan="1">ECMO+BH</td><td align="center" rowspan="1" colspan="1">ECMO bridge to bridge: 480 hours<break/>BH: 330
hours</td><td align="center" rowspan="1" colspan="1">MCD</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">CHD (SV)</td><td align="center" rowspan="1" colspan="1">ECMO</td><td align="center" rowspan="1" colspan="1">123</td><td align="center" rowspan="1" colspan="1">MCD</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">MCP</td><td align="center" rowspan="1" colspan="1">CP+ECMO</td><td align="center" rowspan="1" colspan="1">Rotaflow bridge to bridge: 48<break/>ECMO bridge
to HTx: 536</td><td align="center" rowspan="1" colspan="1">MOD</td><td align="center" rowspan="1" colspan="1">ECPR immediate post-HTx</td></tr><tr><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">CHD (SV)</td><td align="center" rowspan="1" colspan="1">ECMO</td><td align="center" rowspan="1" colspan="1">223</td><td align="center" rowspan="1" colspan="1">MCD</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">CHD (PA/VSD)</td><td align="center" rowspan="1" colspan="1">ECMO</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">Sepsis</td><td align="center" rowspan="1" colspan="1">__</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>BH=Berlin Heart Excor<sup>&#x000ae;</sup>; CP=centrifugal pump;
ECMO=extracorporeal membrane oxygenation; HTx=heart transplantation;
MCD=massive cerebral damage; MCP=cardiomyopathy; MCS=mechanical
cardiac support; MOD=multiple organs disfunction; PA/VSD=pulmonary
atresia with ventricular septal defect; SV=single ventricle
physiology</p></fn></table-wrap-foot></table-wrap><p>Sixteen (55.2%) patients had at least one resuscitated cardiac arrest before MCS
implant. Any kind of cerebral damage was identified in 17 (58.6%) patients. On
the other hand, circuit thrombosis or preoperative cardiac arrest were not risk
factors for cerebral damage (<italic>P</italic>=0.9 and <italic>P</italic>=0.6,
respectively).</p><p>Seven patients died from MCD, five post-Htx (<xref rid="t3" ref-type="table">Table 3</xref>) and two during CP run. Six other patients affected by
cerebral damage died during MCS run, but the cerebral damage was not the main
cause of death in these patients.</p><p>Among the eight patients that were discharged home, four presented some kind of
cerebral damage. Three of them did not have any sequelae, but one patient
suffered significant motor impairment and needed a specialized assistance at
home after discharge.</p><p>Other complications during MCS run included infection in any site in 13 (44.8%)
patients, but none were mediastinitis or cannulae related infection. Respiratory
tract (6 cases), blood stream infection (4 cases) and urinary tract (3 cases)
were the identified sites of infection.</p><p>In seven (24.1%) patients, circuit thrombus was identified and six of them were
submitted to circuit replacement. One patient presented sudden massive ECMO
circuit thrombosis and circuit change was impossible leading to death. No
mechanical device failure was detected, except due to thrombosis.</p><p>Six (20.1%) patients presented increased mediastinal bleeding and need for chest
re-exploration. AKI was observed in 16 (55.2%) patients and among them, 12 (75%)
had already presented AKI before MCS implantation. Mortality in AKI patients was
94% compared to 46% in preserved renal function cases
(<italic>P</italic>=0.01).</p><p>It was not observed any case of significant ventricular function recovery leading
to MCS discontinuation. On the other hand, 11 patients died while on MCS, seven
due to MODs, two due to massive cerebral stroke, one due to sepsis and one due
to circuit thrombosis. Univariate analysis showed AKI during hospitalization and
major bleeding as a risk factor while multivariate analysis identified AKI as a
predictor of death during support (OR=50.8; IC: 1.9-1370;
<italic>P</italic>=0.02).</p><p>Regarding survival to hospital discharge, univariate analysis showed BNP over
1000 post-MCS, SIRS, and AKI as risk factors, but multivariable analysis and
Binary logistic regression identified that only AKI during hospitalization was a
predictive variable of mortality (OR=22.6 [CI=1.04-494.6];
<italic>P</italic>=0.04; <xref rid="t4" ref-type="table">Table 4</xref>).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Univariate and multivariate analysis of death.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Univariate<break/>OR (CI)</th><th align="center" rowspan="1" colspan="1">Univariate<break/><italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">Multivariate <break/>OR (CI)</th><th align="center" rowspan="1" colspan="1">Multivariate <break/><italic>P
</italic>value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BNP post-MCS</td><td align="center" rowspan="1" colspan="1">3.1 (1.1-62)</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">3.2 (0.1-81)</td><td align="center" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" rowspan="1" colspan="1">SIRS</td><td align="center" rowspan="1" colspan="1">9.5 (1.3-71)</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">9.6 (0.3-300)</td><td align="center" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">AKI</td><td align="center" rowspan="1" colspan="1">17.5 (1.8-175)</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">22.6 (1.04-494)</td><td align="center" rowspan="1" colspan="1">0.047</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>AKI=acute kidney injury; BNP=brain natriuretic peptide; CI=confidence
interval; MCS=mechanical cardiac support; OR=odds ratio;
STD=standard deviation</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Pediatric and congenital HTx programs have an intrinsic complexity that mixes
elective dilated cardiomyopathy patients with cardiogenic shock and complicated
congenital hearts. Besides that, waiting time on list tends to be a lot longer than
that for bigger patients, due to the donor scarcity<sup>[</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>,</sup><sup><xref rid="r16" ref-type="bibr">16</xref></sup><sup>]</sup>.</p><p>Definitely, heart failure pediatric patients that present with a critically ill
condition have a bad prognosis, especially in our environment. Our group previously
reported less than 10% on 30-day survival in non-supported cardiogenic shock
cohort<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>]</sup>.</p><p>The International Society for Heart and Lung Transplantation report demonstrates that
the number of pediatric HTx previously supported by MCS grows exponentially every
year<sup>[</sup><sup><xref rid="r8" ref-type="bibr">8</xref></sup><sup>]</sup>.</p><p>Although facing a serious public health financing crisis in our country, especially
concerning new technology, institutional politics stated that MCS should be
implemented in our HTx program. Counting almost exclusively with ECMO circuits and
centrifugal pumps (Rotaflow&#x000ae;, Maquet Getting Group, Rasttat, Germany) was
possible to offer an alternative to the proven failed conventional treatment to
these patients.</p><p>It was necessary a lot of commitment and investment in staff training leading to
improving results with MCS previously demonstrated in a series of post-cardiotomy
ECMO<sup>[</sup><sup><xref rid="r17" ref-type="bibr">17</xref></sup><sup>]</sup>. Paracorporeal VAD (Berlin Heart Excor&#x000ae;) and
Centrimag (Thoratec Inc, USA) were available only for insurance covered patients
that represent the vast minority of our patients.</p><p>As short-term MCS, ECMO and centrifugal pump were used, while Berlin Heart
Excor&#x000ae; was the only long-term device implanted in this initial experience,
available in selected insurance covered patients.</p><p>Our initial results showed an improvement in survival to HTx (55.2%) in these
patients compared to our historical cohort where a 10% survival to HTx was
observed<sup>[</sup><sup><xref rid="r7" ref-type="bibr">7</xref></sup><sup>]</sup>. Although these results cannot be compared to
developed countries' experience<sup>[</sup><sup><xref rid="r18" ref-type="bibr">18</xref></sup><sup>,</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>]</sup>, it may be considered the first step towards a
successful program.</p><p>Concerning that, during the initial experience with Berlin Heart for pediatric
patients, the results were very unsatisfactory with a 100% mortality for patients
aged less than one year<sup>[</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup><sup>]</sup>. Therefore, after the learning curve and program
adjustments in cannulation and avoidance of late indications, their results improved
dramatically<sup>[</sup><sup><xref rid="r20" ref-type="bibr">20</xref></sup><sup>,</sup><sup><xref rid="r21" ref-type="bibr">21</xref></sup><sup>]</sup>.</p><p>Long-term MCS is not routinely available for government or insurance funded patients.
This scenario imposes late indications for MCS as a bridge to HTx, mainly in
patients in critically-ill condition (INTERMACS levels 1 and 2) and using short-term
MCS what might, in part, explain suboptimal results. Indisputably, most of these
issues were caused by the lack of long-term support, leading to long courses of
short-term MCS and its well-known complications. Even Berlin Heart Excor&#x000ae;
patients in our series were supported for a considerable amount of time on ECMO
while waiting for bureaucratic issues. That lead to a 50% mortality during Berlin
Heart run caused by sepsis and multi-organ failure.</p><p>Recent data suggest that patients who underwent ECMO support have inferior
post-transplant survival when compared to those who underwent VAD bridge to
transplantation or direct transplantation. Patients in ECMO group had a lower median
age and were significantly smaller<sup>[</sup><sup><xref rid="r16" ref-type="bibr">16</xref></sup><sup>]</sup>.</p><p>Meanwhile, between 2006 and 2011, Great Britain had a fourfold increase in their
Berlin Heart use in the pediatric population. A retrospective study of their first
7-year experience in 102 children who received Berlin Heart Excor&#x000ae; support,
84% survived to transplant or explant of the VAD, and 81% survived to
discharge<sup>[</sup><sup><xref rid="r18" ref-type="bibr">18</xref></sup><sup>]</sup>.</p><p>As the first report from PediMACS, analyzing 200 pediatric patients supported with
durable VADs, showed a 1-year survival rate of 81%. Approximately 60% of all
patients were transplanted in the 6<sup>th</sup> month and 75% in the
12<sup>th</sup> month. On the other hand, survival was significantly lower in
patients who were in INTERMACS level 1<sup>[</sup><sup><xref rid="r19" ref-type="bibr">19</xref></sup><sup>]</sup>, what might in part explain our high
mortality.</p><p>It is well known that there is a considerable gap between excellence medical centers
accomplishments and Latin America follow through<sup>[</sup><sup><xref rid="r22" ref-type="bibr">22</xref></sup><sup>]</sup>. Nevertheless, as in
Brazil, some isolated efforts in Argentina and Colombia are noticed in this
direction leading to promising results, as the recently published Garrahan's group
initial experience with MCS<sup>[</sup><sup><xref rid="r23" ref-type="bibr">23</xref></sup><sup>]</sup>.</p><p>Even though, a lot of concern was raised regarding our mortality after MCS patients
HTx. A 37.5% 30-day mortality rate was much higher than the less than 10% mortality
observed in non-MCS supported patients previously reported by our
group<sup>[</sup><sup><xref rid="r24" ref-type="bibr">24</xref></sup><sup>]</sup>.</p><p>Trying to understand the results we noticed that Htx was considered and even
performed in very sick patients supported with MCS. At that time, neglected
neurologic damage and underestimated multiple organ dysfunctions drove us to HTx in
irreversible non-cardiac malfunctions.</p><p>Although a high percentage of SIRS and cerebral damage was identified in this series,
AKI was the only identified isolated risk factor for mortality. Nevertheless, it is
well known that AKI and MODs are correlated.</p><p>That fact led us to improve our protocol and withdraw patients from the waiting list
after the initiation of MCS and re-listing them only after better neurologic and
multi organic assessment, preferably with spontaneous breathing patients.</p><p>Still, new challenges remain regarding the incorporation of MCS by Latin America
centers. Apart from financial support, continuous education and training are
required to use these devices and is the key point to achieve excellence centres'
results. International partnership plays an important role in this scenario, where
foreign assistance should be adjusted to the local context avoiding dropping a
replica of a proven model into an obsolete system.</p><p>Limited resources are a barrier to the development of academic, teaching, and
cost-effectiveness MCS programs in Latin America. These programs should be designed
based on the local needs, centralized in active transplants centers and financed by
the public national systems.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Our initial results showed that MCS was able to bridge most INTERMACS 1/2 pediatric
and congenital heart patients to HTx. The poor clinical condition of this population
and the lack of largely available long-term MCS could explain the sub-optimal
mortality observed in this series, where AKI was identified as a risk factor.</p><table-wrap id="t6" orientation="portrait" position="float"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">LAM</td><td align="left" valign="top" rowspan="1" colspan="1">Concept/design; drafting article;
statistics, data interpretation; final approval of the manuscript
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GVRS</td><td align="left" valign="top" rowspan="1" colspan="1">Data collection; data interpretation;
final approval of the manuscript version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LFC</td><td align="left" valign="top" rowspan="1" colspan="1">Concept/design; data interpretation; final
approval of the manuscript version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ALT</td><td align="left" valign="top" rowspan="1" colspan="1">Statistics; final approval of the
manuscript version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CT</td><td align="left" valign="top" rowspan="1" colspan="1">Data interpretation; final approval of the
manuscript version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GF</td><td align="left" valign="top" rowspan="1" colspan="1">Data collection; final approval of the
manuscript version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MRM</td><td align="left" valign="top" rowspan="1" colspan="1">Data analysis; final approval of the
manuscript version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JGP</td><td align="left" valign="top" rowspan="1" colspan="1">Data interpretation; final approval of the
manuscript version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EA</td><td align="left" valign="top" rowspan="1" colspan="1">Concept/design, critical revision of the
manuscript; final approval of the manuscript version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FRBGG</td><td align="left" valign="top" rowspan="1" colspan="1">Concept/design, critical revision of
manuscript; final approval of the manuscript version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FBJ</td><td align="left" valign="top" rowspan="1" colspan="1">Final approval of the manuscript version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MBJ</td><td align="left" valign="top" rowspan="1" colspan="1">Critical revision of the manuscript; final
approval of the version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Cardiovascular Surgery Division, Instituto do
Cora&#x000e7;&#x000e3;o do Hospital das Cl&#x000ed;nicas da Faculdade de Medicina
da Universidade de S&#x000e3;o Paulo (InCor-HCFMUSP), S&#x000e3;o Paulo, SP,
Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="other"><p>Fast Track Publication</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossano</surname><given-names>JW</given-names></name><name><surname>Jang</surname><given-names>GY</given-names></name></person-group><article-title>Pediatric heart failure: current state and future
possibilities</article-title><source>Korean Circ J</source><year>2015</year><volume>45</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25653697</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipshultz</surname><given-names>SE</given-names></name><name><surname>Sleeper</surname><given-names>LA</given-names></name><name><surname>Towbin</surname><given-names>JA</given-names></name><name><surname>Lowe</surname><given-names>AM</given-names></name><name><surname>Orav</surname><given-names>EJ</given-names></name><name><surname>Cox</surname><given-names>GF</given-names></name><etal/></person-group><article-title>The incidence of pediatric cardiomyopathy in two regions of the
United States</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>17</issue><fpage>1647</fpage><lpage>1655</lpage><pub-id pub-id-type="pmid">12711739</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nugent</surname><given-names>AW</given-names></name><name><surname>Daubeney</surname><given-names>PE</given-names></name><name><surname>Chondros</surname><given-names>P</given-names></name><name><surname>Carlin</surname><given-names>JB</given-names></name><name><surname>Cheung</surname><given-names>W</given-names></name><name><surname>Wilkinson</surname><given-names>LC</given-names></name><etal/><collab>National Australian Childhood Cardiomyopathy Study</collab></person-group><article-title>The epidemiology of childhood cardiomyopathy in
Australia</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><issue>17</issue><fpage>1639</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">12711738</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>RE</given-names></name><name><surname>Fenton</surname><given-names>MJ</given-names></name><name><surname>Ridout</surname><given-names>DA</given-names></name><name><surname>Burch</surname><given-names>M</given-names></name><collab>British Congenital Cardiac Association</collab></person-group><article-title>New-onset heart failure due to heart muscle disease in childhood:
a prospective study in the United Kingdom and Ireland</article-title><source>Circulation</source><year>2008</year><volume>117</volume><issue>1</issue><fpage>79</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">18086928</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dipchand</surname><given-names>A</given-names></name><name><surname>Cecere</surname><given-names>R</given-names></name><name><surname>Delgado</surname><given-names>D</given-names></name><name><surname>Dore</surname><given-names>A</given-names></name><name><surname>Giannetti</surname><given-names>N</given-names></name><name><surname>Haddad</surname><given-names>H</given-names></name><etal/></person-group><article-title>Canadian consensus on cardiac transplantation in pediatric and
adult congenital heart disease patients 2004: executive
summary</article-title><source>Can J Cardiol</source><year>2005</year><volume>21</volume><issue>13</issue><fpage>1145</fpage><lpage>1147</lpage><pub-id pub-id-type="pmid">16308587</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azeka</surname><given-names>E</given-names></name><name><surname>Jatene</surname><given-names>MB</given-names></name><name><surname>Jatene</surname><given-names>IB</given-names></name><name><surname>Horowitz</surname><given-names>ES</given-names></name><name><surname>Branco</surname><given-names>KC</given-names></name><name><surname>Souza Neto</surname><given-names>JD</given-names></name><etal/><collab>Sociedade Brasileira de Cardiologia</collab></person-group><article-title>I Guidelines of heart failure and heart transplantation in the
fetus, in children and adults with congenital cardiopathy, The Brazilian
Society of Cardiology</article-title><source>Arq Bras Cardiol</source><year>2014</year><volume>103</volume><issue>6</issue><supplement>Suppl 2</supplement><fpage>1</fpage><lpage>126</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jatene</surname><given-names>MB</given-names></name><name><surname>Miana</surname><given-names>LA</given-names></name><name><surname>Pessoa</surname><given-names>AJ</given-names></name><name><surname>Riso</surname><given-names>A</given-names></name><name><surname>Azeka</surname><given-names>E</given-names></name><name><surname>Tanamati</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pediatric heart transplantation in refractory cardiogenic shock:
a critical analysis of feasibility, applicability and
results</article-title><source>Arq Bras Cardiol</source><year>2008</year><volume>90</volume><issue>5</issue><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">18516404</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caneo</surname><given-names>LF</given-names></name><name><surname>Jatene</surname><given-names>MB</given-names></name></person-group><article-title>Pediatric mechanical circulatory support systems in Latin
America</article-title><source>Artif Organs</source><year>2016</year><volume>40</volume><issue>10</issue><fpage>925</fpage><lpage>928</lpage><pub-id pub-id-type="pmid">27739598</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandica</surname><given-names>E</given-names></name><name><surname>Blanz</surname><given-names>U</given-names></name><name><surname>Mime</surname><given-names>LB</given-names></name><name><surname>Schultz-Kaizler</surname><given-names>U</given-names></name><name><surname>Kececioglu</surname><given-names>D</given-names></name><name><surname>Haas</surname><given-names>N</given-names></name><etal/></person-group><article-title>Long-term mechanical circulatory support in pediatric
patients</article-title><source>Artif Organs</source><year>2016</year><volume>40</volume><issue>3</issue><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">26411865</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>I</given-names></name><name><surname>Burki</surname><given-names>S</given-names></name><name><surname>Zafar</surname><given-names>F</given-names></name><name><surname>Morales</surname><given-names>DL</given-names></name></person-group><article-title>Pediatric ventricular assist devices</article-title><source>J Thorac Dis</source><year>2015</year><volume>7</volume><issue>12</issue><fpage>2194</fpage><lpage>2202</lpage><pub-id pub-id-type="pmid">26793341</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandolfo</surname><given-names>F</given-names></name><name><surname>De Rita</surname><given-names>F</given-names></name><name><surname>Hasan</surname><given-names>A</given-names></name><name><surname>Griselli</surname><given-names>M</given-names></name></person-group><article-title>Mechanical circulatory support in pediatrics</article-title><source>Ann Cardiothorac Surg</source><year>2014</year><volume>3</volume><issue>5</issue><fpage>507</fpage><lpage>512</lpage><pub-id pub-id-type="pmid">25452912</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dipchand</surname><given-names>AI</given-names></name><name><surname>Kirk</surname><given-names>R</given-names></name><name><surname>Edwards</surname><given-names>LB</given-names></name><name><surname>Kucheryavaya</surname><given-names>AY</given-names></name><name><surname>Benden</surname><given-names>C</given-names></name><name><surname>Christie</surname><given-names>JD</given-names></name><etal/><collab>International Society for Heart and Lung Transplantation</collab></person-group><article-title>The Registry of the International Society for Heart and Lung
Transplantation: Sixteenth Official Pediatric Heart Transplantation
Report--2013; focus theme: age</article-title><source>J Heart Lung Transplant</source><year>2013</year><volume>32</volume><issue>10</issue><fpage>979</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">24054806</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Can&#x000ea;o</surname><given-names>LF</given-names></name><name><surname>Miana</surname><given-names>LA</given-names></name><name><surname>Tanamati</surname><given-names>C</given-names></name><name><surname>Penha</surname><given-names>JG</given-names></name><name><surname>Shimoda</surname><given-names>MS</given-names></name><name><surname>Azeka</surname><given-names>E</given-names></name><etal/></person-group><article-title>Use of short-term circulatory support as a bridge in pediatric
heart transplantation</article-title><source>Arq Bras Cardiol</source><year>2015</year><volume>104</volume><issue>1</issue><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">25372474</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lequier</surname><given-names>L</given-names></name><name><surname>Massicotte</surname><given-names>MP</given-names></name></person-group><article-title>Monitoring of anticoagulation in extracorporeal membrane
oxygenation: is anti-Xa the new activated clotting time?</article-title><source>Pediatr Crit Care Med</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>87</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">25560288</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutherland</surname><given-names>SM</given-names></name><name><surname>Byrnes</surname><given-names>JJ</given-names></name><name><surname>Kothari</surname><given-names>M</given-names></name><name><surname>Longhurst</surname><given-names>CA</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>P</given-names></name><etal/></person-group><article-title>AKI in hospitalized children: comparing the pRIFLE, AKIN, and
KDIGO definitions</article-title><source>Clin J Am Soc Nephrol</source><year>2015</year><volume>10</volume><issue>4</issue><fpage>554</fpage><lpage>561</lpage><pub-id pub-id-type="pmid">25649155</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wehman</surname><given-names>B</given-names></name><name><surname>Stafford</surname><given-names>KA</given-names></name><name><surname>Bittle</surname><given-names>GJ</given-names></name><name><surname>Kon</surname><given-names>ZN</given-names></name><name><surname>Evans</surname><given-names>CF</given-names></name><name><surname>Rajagopal</surname><given-names>K</given-names></name><etal/></person-group><article-title>Modern outcomes of mechanical circulatory support as bridge to
pediatric heart transplantation</article-title><source>Ann Thorac Surg</source><year>2016</year><volume>101</volume><issue>6</issue><fpage>2321</fpage><lpage>2327</lpage><pub-id pub-id-type="pmid">26912304</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miana</surname><given-names>LA</given-names></name><name><surname>Can&#x000ea;o</surname><given-names>LF</given-names></name><name><surname>Tanamati</surname><given-names>C</given-names></name><name><surname>Penha</surname><given-names>JG</given-names></name><name><surname>Guimar&#x000e3;es</surname><given-names>VA</given-names></name><name><surname>Miura</surname><given-names>N</given-names></name><etal/></person-group><article-title>Post-cardiotomy ECMO in pediatric and congenital heart surgery:
impact of team training and equipment in the results</article-title><source>Rev Bras Cir Cardiovasc</source><year>2015</year><volume>30</volume><issue>4</issue><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">27163414</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cassidy</surname><given-names>J</given-names></name><name><surname>Dominguez</surname><given-names>T</given-names></name><name><surname>Haynes</surname><given-names>S</given-names></name><name><surname>Burch</surname><given-names>M</given-names></name><name><surname>Kirk</surname><given-names>R</given-names></name><name><surname>Hoskote</surname><given-names>A</given-names></name><etal/></person-group><article-title>A longer waiting game: bridging children to heart transplant with
the Berlin Heart EXCOR device: the United Kingdom experience</article-title><source>J Heart Lung Transplant</source><year>2013</year><volume>32</volume><issue>11</issue><fpage>1101</fpage><lpage>1106</lpage><pub-id pub-id-type="pmid">24060499</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blume</surname><given-names>ED</given-names></name><name><surname>Rosenthal</surname><given-names>DN</given-names></name><name><surname>Rossano</surname><given-names>JW</given-names></name><name><surname>Baldwin</surname><given-names>JT</given-names></name><name><surname>Eghtesady</surname><given-names>P</given-names></name><name><surname>Morales</surname><given-names>DL</given-names></name><etal/><collab>PediMACS Investigators</collab></person-group><article-title>Outcomes of children implanted with ventricular assist devices in
the United States: First analysis of the Pediatric Interagency Registry for
Mechanical Circulatory Support (PediMACS)</article-title><source>J Heart Lung Transplant</source><year>2016</year><volume>35</volume><issue>5</issue><fpage>578</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">27009673</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiller</surname><given-names>B</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>H&#x000fc;bler</surname><given-names>M</given-names></name><name><surname>Lemmer</surname><given-names>J</given-names></name><name><surname>Nagdyman</surname><given-names>N</given-names></name><name><surname>Redlin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pneumatic pulsatile ventricular assist devices in children under
1 year of age</article-title><source>Eur J Cardiothorac Surg</source><year>2005</year><volume>28</volume><issue>2</issue><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">15949952</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hetzer</surname><given-names>R</given-names></name><name><surname>Potapov</surname><given-names>EV</given-names></name><name><surname>Stiller</surname><given-names>B</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>H&#x000fc;bler</surname><given-names>M</given-names></name><name><surname>Lemmer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Improvement in survival after mechanical circulatory support with
pneumatic pulsatile ventricular assist devices in pediatric
patients</article-title><source>Ann Thorac Surg</source><year>2006</year><volume>82</volume><issue>3</issue><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">16928509</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Can&#x000ea;o</surname><given-names>LF</given-names></name><name><surname>Neirotti</surname><given-names>RA</given-names></name></person-group><article-title>ECMO: improving our results by chasing the
rabbits</article-title><source>Braz J Cardiovasc Surg</source><year>2015</year><volume>30</volume><issue>6</issue><fpage>657</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">26934407</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Moreno</surname><given-names>GE</given-names></name><name><surname>Magliola</surname><given-names>R</given-names></name><name><surname>Pil&#x000e1;n</surname><given-names>ML</given-names></name><name><surname>Althabe</surname><given-names>M</given-names></name><name><surname>Balestrini</surname><given-names>M</given-names></name><name><surname>Lenz</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Mechanical circulatory support in pediatrics</article-title><comment>Experience at the Dr. Juan P. Garrahan Pediatric Hospital</comment><publisher-loc>Argentina</publisher-loc><source>Arch Cardiol Mex</source><year>2014</year><volume>84</volume><issue>4</issue><fpage>256</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">25001058</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miana</surname><given-names>LA</given-names></name><name><surname>Azeka</surname><given-names>E</given-names></name><name><surname>Can&#x000ea;o</surname><given-names>LF</given-names></name><name><surname>Turquetto</surname><given-names>AL</given-names></name><name><surname>Tanamati</surname><given-names>C</given-names></name><name><surname>Penha</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Pediatric and congenital heart transplant: twenty-year experience
in a tertiary Brazilian hospital</article-title><source>Rev Bras Cir Cardiovasc</source><year>2014</year><volume>29</volume><issue>3</issue><fpage>322</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">25372904</pub-id></element-citation></ref></ref-list></back></article>